Adial Pharmaceuticals, Inc. Income (Loss) from Equity Method Investments
Adial Pharmaceuticals, Inc. (ADIL) reported Income (Loss) from Equity Method Investments of -$181.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$181.00K.
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$67.97K.
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was $406.71K.
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was -$76.92K.
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2025 was $492.13K.
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2024 was -$552.18K.
- Adial Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2023 was -$193.88K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 3 month as first filed | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 6 month as first filed | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$181.00K 10-Q · filed 2026-08-14 | -$249.00K 10-Q · filed 2026-08-14 | $157.74K derived: sum of 3 quarters · filed 2026-08-14 | $80.82K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$67.97K 10-Q · filed 2026-05-08 | $338.74K derived: sum of 2 quarters · filed 2026-05-08 | $261.82K derived: sum of 3 quarters · filed 2026-05-08 | $162.82K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $406.71K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-05-08 | $329.79K derived: sum of 2 quarters · filed 2026-05-08 | $230.79K derived: sum of 3 quarters · filed 2026-08-14 | $67.97K 10-Q · filed 2026-05-08 | -$492.13K 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$76.92K 10-Q · filed 2025-11-13 | -$175.92K derived: sum of 2 quarters · filed 2026-08-14 | -$338.74K 10-Q · filed 2025-11-13 | $492.13K 10-K · filed 2026-03-05 | |||
| 2025-06-30 | -$99.00K 10-Q · filed 2026-08-14 | -$98.73K 10-Q · filed 2025-08-13 | -$262.00K 10-Q · filed 2026-08-14 | -$261.82K 10-Q · filed 2025-08-13 | -$370.91K derived: sum of 3 quarters · filed 2026-08-14 | -$401.93K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$163.09K 10-Q · filed 2026-05-08 | -$271.91K derived: sum of 2 quarters · filed 2026-05-08 | -$302.93K derived: sum of 3 quarters · filed 2026-05-08 | -$525.40K derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | -$108.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$139.84K derived: sum of 2 quarters · filed 2026-03-05 | -$362.31K derived: sum of 3 quarters · filed 2026-03-05 | -$552.18K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$31.02K 10-Q · filed 2025-11-13 | -$253.50K derived: sum of 2 quarters · filed 2025-11-13 | -$443.37K 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | -$222.47K 10-Q · filed 2025-08-13 | -$412.34K 10-Q · filed 2025-08-13 | |||||
| 2024-03-31 | -$189.87K 10-Q · filed 2025-05-14 | ||||||
| 2023-12-31 | -$193.88K 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |